- Durata Therapeutics (DRTX) says the FDA has approved its Dalvance antibiotic for the treatment of patients with acute bacterial skin and skin structure infections.
- Dalvance is the first drug with the qualified infectious disease product designation to receive FDA approval.
- A March FDA advisory panel approval also had given a favorable review to a rival product from Cubist Pharmaceuticals (CBST); the FDA is set to rule on the CBST drug shortly.
- DRTX shares halted.
at Zacks.com (Nov 17, 2014)